Valvular Disease Management in Patients with Continuous-Flow Left Ventricular Assist Device
Shusaku Maeda(The University of Osaka), Yoshiki Sawa(Osaka Police Hospital), Köichi Toda(The University of Osaka), Shigeru Miyagawa(The University of Osaka), Takehisa Ueno(The University of Osaka), Hironobu Hata(Hokkaido University), Satoshi Kainuma(National Cerebral and Cardiovascular Center), Shohei Yoshida(Okayama University), Ai Kawamura(Max Planck Institute for Heart and Lung Research), Toru Kuratani, Y. Yoshikawa(The University of Osaka), Takuji Kawamura(The University of Osaka)
Cited by 0
Related Papers
In vivo transfection of cis element “decoy” against nuclear factor- κB binding site prevents myocardial infarction
|Nature Medicine|1997|589
Hepatocyte growth factor gene therapy of liver cirrhosis in rats
|Nature Medicine|1999|588
JCS/JSCS/JATS/JSVS 2020 Guidelines on the Management of Valvular Heart Disease
|Circulation Journal|2020|363
PDK1 inhibition is a novel therapeutic target in multiple myeloma
|British Journal of Cancer|2012|138
Thoracic and cardiovascular surgeries in Japan during 2018
|General Thoracic and Cardiovascular Surgery|2020|123